Savara Inc Segments Disclosure
13. Segment Reporting
We follow the accounting guidance of ASC Topic 280, Segment Reporting, which establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise engaging in business activities for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision-makers in deciding how to allocate resources and assess performance. The Company’s chief operating decision maker (“CODM”) has been identified as the , who reviews consolidated results including operating expenses and operating losses at a consolidated level only. The Company and its CODM do not distinguish between potential markets for the purpose of making decisions about resource allocation and performance assessment of its sole pre-revenue development program, MOLBREEVI, for the treatment of autoimmune PAP. Therefore, the Company has only one operating segment and one reportable segment, specialty pharmaceuticals within the respiratory system. The Company's only significant long-lived asset, IPR&D, is located in Denmark, and the Company currently does not generate any revenues and its operating expenses and losses are viewed on a consolidated basis by the CODM. Therefore, no geographical segments are presented. In addition to the significant expense categories included on the Company's
consolidated statements of operations, refer below for disaggregated amounts that comprise research and development expenses and the segment net loss (in thousands):
|
|
Year Ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Operating expenses: |
|
|
|
|
|
|
||
Research and development operating costs and expenses excluding |
|
|
|
|
|
|
||
Primary program research and development expenses (a) |
|
$ |
61,744 |
|
|
$ |
59,325 |
|
Other research and development expenses: |
|
|
|
|
|
|
||
Payroll and benefits |
|
|
13,549 |
|
|
|
11,933 |
|
Occupancy and other overhead and operating costs |
|
|
2,056 |
|
|
|
2,318 |
|
Total other research and development expenses |
|
|
15,605 |
|
|
|
14,251 |
|
Research and development operating costs and expenses excluding |
|
|
77,349 |
|
|
|
73,576 |
|
General and administrative expense excluding non-cash stock-based |
|
|
31,690 |
|
|
|
19,630 |
|
Other segment income (expense), net (b) |
|
|
9,798 |
|
|
|
2,675 |
|
Segment net loss |
|
$ |
(118,837 |
) |
|
$ |
(95,881 |
) |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 13, 2026 | Showing above |
| 2024 | Mar 27, 2025 | |
| 2016 | Mar 6, 2017 | |
| 2015 | Mar 14, 2016 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.